FDA Inspection 1207681 — Reapplix
The FDA completed an inspection of Reapplix on May 11, 2023 in Birkerod. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- May 11, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Birkerod (Denmark)